Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Passes Above 200 Day Moving Average - Here's What Happened

Key Points

• Enanta Pharmaceuticals shares moved above their 200-day moving average of $13.46, reaching $13.50 before closing at $13.13.
• Analyst opinions remain mixed, but the overall consensus is “Moderate Buy” with a $19.50 price target; six analysts rate the stock a Buy versus one Sell rating.
• The company missed quarterly expectations, reporting an adjusted loss of $0.67 per share versus the $0.51 expected and revenue of $14.36 million versus $16.76 million estimated. Institutional investors own approximately 95% of outstanding shares.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report)'s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $13.46 and traded as high as $13.50. Enanta Pharmaceuticals shares last traded at $13.13, with a volume of 194,820 shares traded.

Analyst Ratings Changes

A number of research firms recently issued reports on ENTA. Wall Street Zen cut Enanta Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, May 31st. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $19.50.

Enanta Pharmaceuticals Stock Performance

The company has a fifty day moving average price of $13.39 and a two-hundred day moving average price of $13.46. The company has a market cap of $382.35 million, a P/E ratio of -5.45 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The company had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. Research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at $32,000. Seven Fleet Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth about $36,000. Legal & General Group Plc bought a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth about $41,000. Strs Ohio acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Enanta Pharmaceuticals by 333.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 2,758 shares during the period. Institutional investors and hedge funds own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source